A Study of LW231 to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Volunteers and Participants With Chronic Hepatitis B Virus Infection

NCT06311734 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

119

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Hepatitis B

Interventions

DRUG: LW231 tablets
DRUG: Placebo

Sponsor

Shanghai Longwood Biopharmaceuticals Co., Ltd.